Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

Phase 2

Conditions: Nausea
Vomiting
Head and Neck Squamous Cell Carcinoma
Radiotherapy Side Effect

Interventions: Drug: Olanzapine

First Posted Date: 2022-01-21

Last Posted Date: 2022-01-21

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 43

Registration Number: NCT05202275

Locations: 🇨🇳
Ye Zhang, Beijing, Beijing, China

Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China

Completed

Conditions: Esophageal Neoplasms

Interventions: Radiation: definitive radiotherapy or definitive chemoradiotherapy

First Posted Date: 2022-01-18

Last Posted Date: 2022-01-18

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 3000

Registration Number: NCT05194371

Locations: 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer

Not Applicable

Conditions: Magnetic Resonance-linac
Stereotactic Ablative RT
Adaptive Radiotherapy
Prostate Cancer
Radiotherapy Side Effect
Localised Disease
Oligometastatic Disease

Interventions: Device: MR-linac

First Posted Date: 2022-01-10

Last Posted Date: 2022-01-10

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 50

Registration Number: NCT05183074

Locations: 🇨🇳
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma

Phase 2

Conditions: Major Wound Complications
Anlotinib
Sarcoma,Soft Tissue
Intensity-modulated Radiotherapy
Extremity
Trunk

Interventions: Drug: Anlotinib hydrochloride

First Posted Date: 2021-12-22

Last Posted Date: 2021-12-22

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT05167994

Locations: 🇨🇳
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above

Phase 3

Conditions: SARS-CoV2 Infection

Interventions: Biological: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)

First Posted Date: 2021-12-21

Last Posted Date: 2022-02-16

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 880

Registration Number: NCT05164731

Locations: 🇨🇳
Mile City Centers for Disease Control and Prevention, Mile, Yunnan, China

Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above

Phase 3

Conditions: SARS-CoV-2 Infection

Interventions: Biological: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)

First Posted Date: 2021-12-20

Last Posted Date: 2022-03-02

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 432

Registration Number: NCT05163652

Locations: 🇨🇳
Anning First People's Hospital, Anning, Yunnan, China

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Phase 2

Not yet recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Neratinib

First Posted Date: 2021-12-13

Last Posted Date: 2021-12-13

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT05154396

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Phase 2

Recruiting

Conditions: Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
Early-stage

Interventions: Drug: Anti-PD-1 monoclonal antibody

First Posted Date: 2021-12-08

Last Posted Date: 2021-12-08

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT05149170

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Phase 2

Conditions: Metastatic Triple-Negative Breast Cancer

Interventions: Drug: Anlotinib
Drug: Capecitabine

First Posted Date: 2021-10-22

Last Posted Date: 2022-01-10

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 35

Registration Number: NCT05089643

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

Phase 3

Recruiting

Conditions: Colo-rectal Cancer

First Posted Date: 2021-10-12

Last Posted Date: 2021-10-12

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 314

Registration Number: NCT05074966

Locations: 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy